董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Howard Clowes | 男 | Director | 71 | 7.67万美元 | 未持股 | 2025-08-07 |
| An van Es Johansson | 女 | Director | 64 | 6.67万美元 | 未持股 | 2025-08-07 |
| Robert Lenk | 男 | Director | 76 | 5.42万美元 | 未持股 | 2025-08-07 |
| Kyle Guse Esq | 男 | Director | 61 | 未披露 | 未持股 | 2025-08-07 |
| Marc H. Hedrick | 男 | President, Chief Executive Officer and Director | 62 | 126.03万美元 | 未持股 | 2025-08-07 |
| Richard J. Hawkins | 男 | Chairman of the Board | 76 | 10.42万美元 | 未持股 | 2025-08-07 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Andrew Sims | 男 | Chief Financial Officer | 52 | 62.11万美元 | 未持股 | 2025-08-07 |
| Marc H. Hedrick | 男 | President, Chief Executive Officer and Director | 62 | 126.03万美元 | 未持股 | 2025-08-07 |
董事简历
中英对照 | 中文 | 英文- Howard Clowes
-
Howard Clowes，自2020年4月1日起担任Plus Therapeutics, Inc.董事会成员。从2005年1月到2018年12月退休，克劳斯一直是DLA Piper（US）LLC律师事务所的合伙人。从1982年到2005年DLA Piper成立，他在DLA Piper的前身公司担任合伙人和合伙人，担任过各种管理职务，包括在公司董事会任职。Clowes先生于2018年1月至2022年5月担任Equalize Health董事会成员和治理委员会主席，并担任AFRAC董事会成员，这两家公司都是专注于全球医疗保健的非营利公司。从2008年到2018年12月，克劳斯曾在位于加利福尼亚州圣何塞的非营利组织硅谷法律基金会的董事会任职，该基金会为有需要的硅谷居民提供免费法律服务，在此期间担任多个职位，包括董事会主席、战略规划和CEO遴选委员会主席。从2017年到2021年，克劳斯在加州大学伯克利分校的伯克利法学院担任讲师，教授一门国际商务谈判课程。克劳斯在加州大学伯克利分校获得法学博士学位，在加州大学圣巴巴拉分校获得实验心理学学士学位。
Howard Clowes,From January 2005 until he retired as a lawyer in December 2018, Mr. Clowes was a partner in the law firm DLA Piper (US) LLC. From 1982 until the formation of DLA Piper in 2005, he was an associate and then a partner in the predecessor firms of DLA Piper, holding various management positions, including serving on its board of directors and its compensation committee. Mr. Clowes served on the board of Equalize Health and as chair of its governance committee from January 2018 to May 2022, and serves on the board of AFRAC, each of which are nonprofit corporations focused on global healthcare. Mr. Clowes served on the board of the Law Foundation of Silicon Valley, a non-profit organization located in San Jose, California, that provides free legal services to Silicon Valley residents in need, from 2008 until December 2018, during which he served in various positions, including President of its board of directors, and Chair of its Strategic Planning and Chief Executive Officer Search Committee. From 2017 to 2021, Mr. Clowes served as a Lecturer at the University of California, Berkeley School of Law, teaching a course in International Business Negotiations. Mr. Clowes earned his J.D. at U.C. Berkeley, his B.A. in Experimental Psychology at U.C. Santa Barbara, and in 2023, Mr. Clowes received his National Association of Corporate Directors Directorship Certification. - Howard Clowes，自2020年4月1日起担任Plus Therapeutics, Inc.董事会成员。从2005年1月到2018年12月退休，克劳斯一直是DLA Piper（US）LLC律师事务所的合伙人。从1982年到2005年DLA Piper成立，他在DLA Piper的前身公司担任合伙人和合伙人，担任过各种管理职务，包括在公司董事会任职。Clowes先生于2018年1月至2022年5月担任Equalize Health董事会成员和治理委员会主席，并担任AFRAC董事会成员，这两家公司都是专注于全球医疗保健的非营利公司。从2008年到2018年12月，克劳斯曾在位于加利福尼亚州圣何塞的非营利组织硅谷法律基金会的董事会任职，该基金会为有需要的硅谷居民提供免费法律服务，在此期间担任多个职位，包括董事会主席、战略规划和CEO遴选委员会主席。从2017年到2021年，克劳斯在加州大学伯克利分校的伯克利法学院担任讲师，教授一门国际商务谈判课程。克劳斯在加州大学伯克利分校获得法学博士学位，在加州大学圣巴巴拉分校获得实验心理学学士学位。
- Howard Clowes,From January 2005 until he retired as a lawyer in December 2018, Mr. Clowes was a partner in the law firm DLA Piper (US) LLC. From 1982 until the formation of DLA Piper in 2005, he was an associate and then a partner in the predecessor firms of DLA Piper, holding various management positions, including serving on its board of directors and its compensation committee. Mr. Clowes served on the board of Equalize Health and as chair of its governance committee from January 2018 to May 2022, and serves on the board of AFRAC, each of which are nonprofit corporations focused on global healthcare. Mr. Clowes served on the board of the Law Foundation of Silicon Valley, a non-profit organization located in San Jose, California, that provides free legal services to Silicon Valley residents in need, from 2008 until December 2018, during which he served in various positions, including President of its board of directors, and Chair of its Strategic Planning and Chief Executive Officer Search Committee. From 2017 to 2021, Mr. Clowes served as a Lecturer at the University of California, Berkeley School of Law, teaching a course in International Business Negotiations. Mr. Clowes earned his J.D. at U.C. Berkeley, his B.A. in Experimental Psychology at U.C. Santa Barbara, and in 2023, Mr. Clowes received his National Association of Corporate Directors Directorship Certification.
- An van Es Johansson
-
自2020年1月1日起在Plus Therapeutics, Inc.董事会任职。2018年9月至2021年3月1日，范埃斯-约翰森博士担任瑞典制药公司AlzeCure Pharma的首席医疗官，该公司主要专注于阿尔茨海默病，之后她从2021年3月开始继续担任AlzeCure Pharma的高级顾问。从2005年5月到2018年9月，范埃斯-约翰森博士在总部位于瑞典斯德哥尔摩的国际罕见病公司Sobi担任了一系列管理职务，责任越来越大，包括从2013年3月到2018年1月担任副总裁兼EMENAR专科护理和合作伙伴产品医疗事务主管。在加入Sobi之前，van Es-Johansson博士曾在大型制药公司和小型生物技术公司担任领导职务，包括罗氏、Pharmacia、礼来、Active Biotech和BioStratum。2004年至2016年，她是Uppsala Bio的科学顾问委员会成员，目前担任IRLAB AB（纳斯达克IRLAB Stockholm）、Savara，Inc.（纳斯达克股票代码：SVRA）、Lumos Pharma, Inc.（纳斯达克股票代码：LUMO）和私人控股的Agendia BV的董事会成员。2016年6月至2021年2月，她还在BioInvent International AB（纳斯达克OMX Stockholm）担任董事会成员。van Es-Johansson博士在荷兰鹿特丹的伊拉斯谟大学获得医学博士学位。
An van Es Johansson,served as the Chief Medical Officer for AlzeCure Pharma, a Swedish pharmaceutical company with a primary focus on Alzheimer's disease, from September 2018 through March 1, 2021, following which she has continued to serve AlzeCure Pharma as a Senior Advisor beginning in March 2021. Since 2021 she has been a Senior Advisor for Sinfonia AB, a Swedish pharmaceutical company with focus on neuroscience. From May 2005 to September 2018, Dr. van Es-Johansson served in a range of executive roles of increasing responsibility at Sobi, an international rare disease company headquartered in Stockholm, Sweden, including as Vice President and Head of EMENAR Medical Affairs for Specialty Care and Partner Products from March 2013 to January 2018. Prior to her time at Sobi, Dr. van Es-Johansson served in leadership positions within large pharmaceutical and smaller biotechnology companies, including Roche, Pharmacia, Eli Lilly, Active Biotech and BioStratum. From 2004 to 2016, she was a member of the Scientific Advisory Board of Uppsala Bio and currently serves on the board of directors of Savara, Inc. (Nasdaq: SVRA), Lumos Pharma, Inc. (Nasdaq: LUMO) and privately held Agendia BV. She also served on the board of directors at BioInvent International AB (Nasdaq: OMX Stockholm: BINV), from June 2016 to February 2021; on the board of directors of Alzecure AB (NASDAQ OMX Stockholm: ALZCUR), from 2017-2020; on the board of directors of Medivir AB (Nasdaq OMX Stockholm: MVIR) from 2019-2022; and on the board of directors of IRLAB AB (Nasdaq OMX Stockholm: IRLAB) from May 2022 to February 2023. Dr. van Es-Johansson received a M.D. from Erasmus University, Rotterdam, The Netherlands. - 自2020年1月1日起在Plus Therapeutics, Inc.董事会任职。2018年9月至2021年3月1日，范埃斯-约翰森博士担任瑞典制药公司AlzeCure Pharma的首席医疗官，该公司主要专注于阿尔茨海默病，之后她从2021年3月开始继续担任AlzeCure Pharma的高级顾问。从2005年5月到2018年9月，范埃斯-约翰森博士在总部位于瑞典斯德哥尔摩的国际罕见病公司Sobi担任了一系列管理职务，责任越来越大，包括从2013年3月到2018年1月担任副总裁兼EMENAR专科护理和合作伙伴产品医疗事务主管。在加入Sobi之前，van Es-Johansson博士曾在大型制药公司和小型生物技术公司担任领导职务，包括罗氏、Pharmacia、礼来、Active Biotech和BioStratum。2004年至2016年，她是Uppsala Bio的科学顾问委员会成员，目前担任IRLAB AB（纳斯达克IRLAB Stockholm）、Savara，Inc.（纳斯达克股票代码：SVRA）、Lumos Pharma, Inc.（纳斯达克股票代码：LUMO）和私人控股的Agendia BV的董事会成员。2016年6月至2021年2月，她还在BioInvent International AB（纳斯达克OMX Stockholm）担任董事会成员。van Es-Johansson博士在荷兰鹿特丹的伊拉斯谟大学获得医学博士学位。
- An van Es Johansson,served as the Chief Medical Officer for AlzeCure Pharma, a Swedish pharmaceutical company with a primary focus on Alzheimer's disease, from September 2018 through March 1, 2021, following which she has continued to serve AlzeCure Pharma as a Senior Advisor beginning in March 2021. Since 2021 she has been a Senior Advisor for Sinfonia AB, a Swedish pharmaceutical company with focus on neuroscience. From May 2005 to September 2018, Dr. van Es-Johansson served in a range of executive roles of increasing responsibility at Sobi, an international rare disease company headquartered in Stockholm, Sweden, including as Vice President and Head of EMENAR Medical Affairs for Specialty Care and Partner Products from March 2013 to January 2018. Prior to her time at Sobi, Dr. van Es-Johansson served in leadership positions within large pharmaceutical and smaller biotechnology companies, including Roche, Pharmacia, Eli Lilly, Active Biotech and BioStratum. From 2004 to 2016, she was a member of the Scientific Advisory Board of Uppsala Bio and currently serves on the board of directors of Savara, Inc. (Nasdaq: SVRA), Lumos Pharma, Inc. (Nasdaq: LUMO) and privately held Agendia BV. She also served on the board of directors at BioInvent International AB (Nasdaq: OMX Stockholm: BINV), from June 2016 to February 2021; on the board of directors of Alzecure AB (NASDAQ OMX Stockholm: ALZCUR), from 2017-2020; on the board of directors of Medivir AB (Nasdaq OMX Stockholm: MVIR) from 2019-2022; and on the board of directors of IRLAB AB (Nasdaq OMX Stockholm: IRLAB) from May 2022 to February 2023. Dr. van Es-Johansson received a M.D. from Erasmus University, Rotterdam, The Netherlands.
- Robert Lenk
-
Robert Lenk，自2020年4月1日起担任Plus Therapeutics, Inc.董事会成员。自2016年起，他担任Lenk Pharmaceuticals，LLC总裁，为制药行业客户提供咨询。伦克博士于1981年在新泽西州普林斯顿与他人共同创立了脂质体公司，后来被Elan Pharmaceuticals收购。脂质体公司上市后，1989年，他作为研发副总裁与他人共同创立了Argus Pharmaceuticals，这是一家专注于癌症和传染病的药物输送公司，直到该公司与另外两家公司合并，成为Aronex Pharmaceuticals。从1995年到2003年，Lenk博士担任Therapeutics 2000，Inc.的总裁兼首席执行官，该公司后来被出售给Coller Capital。Lenk博士于2004年加入Luna Innovations，在那里他担任Nanoworks部门的总裁，直到2010年。2010年，伦克博士以首席科学官的身份加入MediVector，Inc.，直到2016年他创办了Lenk Pharmaceuticals，LLC，这是一家他目前工作的制药开发咨询公司。他目前还在PoP Biotechnology的董事会任职，该公司是一家私营公司，开发基于专有卟啉脂质体纳米颗粒技术的疫苗和癌症疗法。伦克博士在麻省理工学院获得博士学位和理学学士学位。
Robert Lenk,Since 2016, he has served as President of Lenk Pharmaceuticals, LLC, providing consulting services to clients in the pharmaceuticals industry. Dr. Lenk co-founded the Liposome Company, in Princeton, New Jersey in 1981 (now part of Elan Pharmaceuticals). After the Liposome Company went public, he co-founded Argus Pharmaceuticals, a drug delivery company focused on cancer and infectious diseases, in 1989 and served as Vice President of Research & Development, until it merged with two other companies to become Aronex Pharmaceuticals. From 1995 to 2003, Dr. Lenk served as President and Chief Executive Officer of Therapeutics 2000, Inc. which was later sold to Coller Capital. Dr. Lenk joined Luna Innovations in 2004 where he served as President of its Nanoworks Division until 2010. In 2010, Dr. Lenk joined MediVector, Inc. as its Chief Science Officer until 2016, when he started Lenk Pharmaceuticals, LLC, a pharmaceutical development consulting company, where he currently works. He also currently serves on the board of PoP Biotechnology, a private company that develops vaccines and cancer therapies based on proprietary porphyrin liposome nanoparticle technology. Dr. Lenk received both his PhD and BSc. From the Massachusetts Institute of Technology. - Robert Lenk，自2020年4月1日起担任Plus Therapeutics, Inc.董事会成员。自2016年起，他担任Lenk Pharmaceuticals，LLC总裁，为制药行业客户提供咨询。伦克博士于1981年在新泽西州普林斯顿与他人共同创立了脂质体公司，后来被Elan Pharmaceuticals收购。脂质体公司上市后，1989年，他作为研发副总裁与他人共同创立了Argus Pharmaceuticals，这是一家专注于癌症和传染病的药物输送公司，直到该公司与另外两家公司合并，成为Aronex Pharmaceuticals。从1995年到2003年，Lenk博士担任Therapeutics 2000，Inc.的总裁兼首席执行官，该公司后来被出售给Coller Capital。Lenk博士于2004年加入Luna Innovations，在那里他担任Nanoworks部门的总裁，直到2010年。2010年，伦克博士以首席科学官的身份加入MediVector，Inc.，直到2016年他创办了Lenk Pharmaceuticals，LLC，这是一家他目前工作的制药开发咨询公司。他目前还在PoP Biotechnology的董事会任职，该公司是一家私营公司，开发基于专有卟啉脂质体纳米颗粒技术的疫苗和癌症疗法。伦克博士在麻省理工学院获得博士学位和理学学士学位。
- Robert Lenk,Since 2016, he has served as President of Lenk Pharmaceuticals, LLC, providing consulting services to clients in the pharmaceuticals industry. Dr. Lenk co-founded the Liposome Company, in Princeton, New Jersey in 1981 (now part of Elan Pharmaceuticals). After the Liposome Company went public, he co-founded Argus Pharmaceuticals, a drug delivery company focused on cancer and infectious diseases, in 1989 and served as Vice President of Research & Development, until it merged with two other companies to become Aronex Pharmaceuticals. From 1995 to 2003, Dr. Lenk served as President and Chief Executive Officer of Therapeutics 2000, Inc. which was later sold to Coller Capital. Dr. Lenk joined Luna Innovations in 2004 where he served as President of its Nanoworks Division until 2010. In 2010, Dr. Lenk joined MediVector, Inc. as its Chief Science Officer until 2016, when he started Lenk Pharmaceuticals, LLC, a pharmaceutical development consulting company, where he currently works. He also currently serves on the board of PoP Biotechnology, a private company that develops vaccines and cancer therapies based on proprietary porphyrin liposome nanoparticle technology. Dr. Lenk received both his PhD and BSc. From the Massachusetts Institute of Technology.
- Kyle Guse Esq
-
Kyle Guse ESQ，自2023年9月起担任纽约证券交易所美国上市的国际消费食品公司DDC Enterprise Ltd.（NYSE：DDC）的首席法务官。2013年1月至2023年5月，Guse先生担任Atossa Therapeutics, Inc.（纳斯达克，ATOS）的首席财务官、总法律顾问和秘书，该公司是一家在纳斯达克上市的生物技术公司，开发乳腺癌的治疗和预防方法。Guse先生的经验包括通过财务、公司治理、证券法和商业化的各个方面为创新型、快速增长的公司提供30年的辅导，特别关注并购和资本市场交易。Guse先生曾在几家最大的国际律师事务所从事法律业务，包括2012年1月至2013年1月在Baker Botts LLP担任合伙人，在此之前，2007年10月至2012年1月在McDermott Will & Emery LLP担任合伙人。在McDermott Will & Emery工作之前，Guse先生曾在Heller Ehrman LLP担任合伙人。Guse先生的职业生涯始于德勤会计师，他是一名不活跃的注册会计师，也是加利福尼亚州和华盛顿州律师协会的成员。Guse先生在萨克拉门托的加州州立大学获得了工商管理学士学位和工商管理硕士学位，并在圣克拉拉大学法学院获得了法学博士学位。
Kyle Guse Esq,has been serving as the Chief Legal Officer of DDC Enterprise Ltd. (NYSE:DDC), an NYSE-American-listed international consumer foods company, since September 2023. From January 2013 to May 2023, Mr. Guse was Chief Financial Officer, General Counsel and Secretary of Atossa Therapeutics, Inc. (Nasdaq, ATOS), a Nasdaq-listed biotechnology company developing treatments and prevention for breast cancer. Mr. Guse's experience includes 30 years of counseling innovative, rapid growth companies through all aspects of finance, corporate governance, securities laws and commercialization, with a particular focus on M&A and capital market transactions. Mr. Guse has practiced law at several of the largest international law firms, including from January 2012 through January 2013 as a partner at Baker Botts LLP and, prior to that, from October 2007 to January 2012, as a partner at McDermott Will & Emery LLP. Before working at McDermott Will & Emery, Mr. Guse served as a partner at Heller Ehrman LLP. Mr. Guse began his career as an accountant at Deloitte and he is an inactive Certified Public Accountant and member of the bars of California and Washington. Mr. Guse earned a B.S. in business administration and an M.B.A. from California State University, Sacramento, and a J.D. from Santa Clara University School of Law. - Kyle Guse ESQ，自2023年9月起担任纽约证券交易所美国上市的国际消费食品公司DDC Enterprise Ltd.（NYSE：DDC）的首席法务官。2013年1月至2023年5月，Guse先生担任Atossa Therapeutics, Inc.（纳斯达克，ATOS）的首席财务官、总法律顾问和秘书，该公司是一家在纳斯达克上市的生物技术公司，开发乳腺癌的治疗和预防方法。Guse先生的经验包括通过财务、公司治理、证券法和商业化的各个方面为创新型、快速增长的公司提供30年的辅导，特别关注并购和资本市场交易。Guse先生曾在几家最大的国际律师事务所从事法律业务，包括2012年1月至2013年1月在Baker Botts LLP担任合伙人，在此之前，2007年10月至2012年1月在McDermott Will & Emery LLP担任合伙人。在McDermott Will & Emery工作之前，Guse先生曾在Heller Ehrman LLP担任合伙人。Guse先生的职业生涯始于德勤会计师，他是一名不活跃的注册会计师，也是加利福尼亚州和华盛顿州律师协会的成员。Guse先生在萨克拉门托的加州州立大学获得了工商管理学士学位和工商管理硕士学位，并在圣克拉拉大学法学院获得了法学博士学位。
- Kyle Guse Esq,has been serving as the Chief Legal Officer of DDC Enterprise Ltd. (NYSE:DDC), an NYSE-American-listed international consumer foods company, since September 2023. From January 2013 to May 2023, Mr. Guse was Chief Financial Officer, General Counsel and Secretary of Atossa Therapeutics, Inc. (Nasdaq, ATOS), a Nasdaq-listed biotechnology company developing treatments and prevention for breast cancer. Mr. Guse's experience includes 30 years of counseling innovative, rapid growth companies through all aspects of finance, corporate governance, securities laws and commercialization, with a particular focus on M&A and capital market transactions. Mr. Guse has practiced law at several of the largest international law firms, including from January 2012 through January 2013 as a partner at Baker Botts LLP and, prior to that, from October 2007 to January 2012, as a partner at McDermott Will & Emery LLP. Before working at McDermott Will & Emery, Mr. Guse served as a partner at Heller Ehrman LLP. Mr. Guse began his career as an accountant at Deloitte and he is an inactive Certified Public Accountant and member of the bars of California and Washington. Mr. Guse earned a B.S. in business administration and an M.B.A. from California State University, Sacramento, and a J.D. from Santa Clara University School of Law.
- Marc H. Hedrick
-
Marc H. Hedrick，于2002年10月加入公司，担任首席科学官。2004年5月，他被任命为公司总裁，2014年4月被任命为首席执行官。自2002年10月加入公司以来，Hedrick博士一直担任Plus Therapeutics，Inc.董事会成员。此前，Hedrick博士曾担任多个行政领导职位，包括2001年至2003年StemSource总裁兼首席执行官，2002年至2004年Macropore生物外科首席科学官兼医疗总监。自2000年以来，Hedrick博士还担任多家公共和私人公司的董事会成员。在他的企业生涯之前，Hedrick博士是加州大学洛杉矶分校的外科和儿科副教授。在加州大学洛杉矶分校期间，Hedrick博士的学术研究获得了NIH的资助以及私人和公共资本，并通过科学出版物和媒体得到了广泛认可。Hedrick医生还拥有一手医生经验，从事普通外科、血管外科和颅面外科手术。Hedrick博士拥有德克萨斯大学西南医学院的医学学位和加州大学洛杉矶分校安德森管理学院的工商管理硕士学位，是一名训练有素的普通、血管和整形外科医生。
Marc H. Hedrick,joined the Company in October 2002 as its Chief Scientific Officer. In May 2004, he was appointed as President of the Company and in April 2014, he was appointed as its Chief Executive Officer. Dr. Hedrick has served as a member of Plus Therapeutics, Inc. board of directors (the "Board") since joining the Company in October 2002. Previously, Dr. Hedrick served in a number of executive leadership positions, including President and Chief Executive Officer of StemSource from 2001 to 2003 and Chief Scientific Officer and Medical Director of Macropore Biosurgery from 2002 to 2004. Dr. Hedrick has also served as a board member for a number of public and private companies since 2000. Prior to his corporate career, Dr. Hedrick was Associate Professor of Surgery and Pediatrics at the University of California, Los Angeles ("UCLA"). While at UCLA, Dr. Hedrick's academic research received both National Institutes of Health funding as well as private and public capitalization and was widely acknowledged through scientific publications and the media. Dr. Hedrick also has first-hand experience as a physician, practicing general, vascular and craniofacial surgery. Dr. Hedrick has a medical degree from The University of Texas Southwestern Medical School and a Master of Business Administration from the UCLA Anderson School of Management and is a trained general, vascular and plastic surgeon. - Marc H. Hedrick，于2002年10月加入公司，担任首席科学官。2004年5月，他被任命为公司总裁，2014年4月被任命为首席执行官。自2002年10月加入公司以来，Hedrick博士一直担任Plus Therapeutics，Inc.董事会成员。此前，Hedrick博士曾担任多个行政领导职位，包括2001年至2003年StemSource总裁兼首席执行官，2002年至2004年Macropore生物外科首席科学官兼医疗总监。自2000年以来，Hedrick博士还担任多家公共和私人公司的董事会成员。在他的企业生涯之前，Hedrick博士是加州大学洛杉矶分校的外科和儿科副教授。在加州大学洛杉矶分校期间，Hedrick博士的学术研究获得了NIH的资助以及私人和公共资本，并通过科学出版物和媒体得到了广泛认可。Hedrick医生还拥有一手医生经验，从事普通外科、血管外科和颅面外科手术。Hedrick博士拥有德克萨斯大学西南医学院的医学学位和加州大学洛杉矶分校安德森管理学院的工商管理硕士学位，是一名训练有素的普通、血管和整形外科医生。
- Marc H. Hedrick,joined the Company in October 2002 as its Chief Scientific Officer. In May 2004, he was appointed as President of the Company and in April 2014, he was appointed as its Chief Executive Officer. Dr. Hedrick has served as a member of Plus Therapeutics, Inc. board of directors (the "Board") since joining the Company in October 2002. Previously, Dr. Hedrick served in a number of executive leadership positions, including President and Chief Executive Officer of StemSource from 2001 to 2003 and Chief Scientific Officer and Medical Director of Macropore Biosurgery from 2002 to 2004. Dr. Hedrick has also served as a board member for a number of public and private companies since 2000. Prior to his corporate career, Dr. Hedrick was Associate Professor of Surgery and Pediatrics at the University of California, Los Angeles ("UCLA"). While at UCLA, Dr. Hedrick's academic research received both National Institutes of Health funding as well as private and public capitalization and was widely acknowledged through scientific publications and the media. Dr. Hedrick also has first-hand experience as a physician, practicing general, vascular and craniofacial surgery. Dr. Hedrick has a medical degree from The University of Texas Southwestern Medical School and a Master of Business Administration from the UCLA Anderson School of Management and is a trained general, vascular and plastic surgeon.
- Richard J. Hawkins
-
Richard J. Hawkins，2007年12月以来担任公司的董事。1982年，Hawkins先生成立了Pharmaco，一个临床研究组织，后来1991年与PPD-Pharmaco的前身合并，PPD-Pharmaco如今也是最大的临床研究组织。1992年，Hawkins先生联合创立了Sensus药物研发，公司开发并且获得了SOMAVERT的监管批准，SOMAVERT是一个获得批准的生长激素拮抗剂，治疗肢端肥大症，目前由辉瑞在美国和欧洲销售，他也一直担任Sensus的董事长到2000年。1994年，Hawkins先生联合创立了Corning Biopro，一家蛋白质制造商，他一直担任董事会成员知道2000年。在2003年9月，Hawkins先生成立了LabNow，一家私营公司，研发芯片实验室传感器技术，他担任LabNow的董事长兼首席执行官一直到2009年10月。Hawkins先生2004年10月以来担任SciClone制药的董事会成员。2011年2月，Hawkins先生成为并且现在还是Lumos制药的首席执行官，这是一家刚起步的制药公司。他曾担任过奥斯汀得克萨斯大学纳米和分子科技中心的总裁顾问委员会成员，并且入选了德克萨斯大学自然科学学院荣誉大厅。Hawkins先生以优异成绩毕业于俄亥俄大学，并且拥有生物学学士学位。
Richard J. Hawkins,founded Pharmaco, a clinical research organization, where he served as its Chairman, President and Chief Executive Officer until 1991 when it merged with the predecessor of PPD-Pharmaco. In 1992, Mr. Hawkins co-founded Sensus Drug Development Corporation, a privately-held company focused on the development of drugs to treat endocrine disorders, which developed and received regulatory approval for SOMAVERT, a growth hormone antagonist approved for the treatment of acromegaly, which is now marketed by Pfizer, Inc. (NYSE:PEE), where he served as Chairman until 2000. In 1994, Mr. Hawkins co-founded Corning Biopro, a contract protein manufacturing firm, where he served on its board until Corning BioPro's sale to Akzo-Nobel, N.V. (OTC:AKZOY), a publicly-held producer of paints, coatings and specialty chemicals, in 2000. In September 2003, Mr. Hawkins founded LabNow, Inc., a privately held company that develops lab-on-a-chip sensor technology, where he served as the Chairman and Chief Executive Officer until October 2009. In February 2011, Mr. Hawkins became Chief Executive Officer, and held the positions of Chief Executive Officer, President and Chairman of Lumos Pharma, Inc. (Nasdaq: LUMO) until the time of its sale in December 2023. Additionally, Mr. Hawkins served on the board of SciClone Pharmaceuticals, Inc. (HKD: SCLN), a publicly-held specialty pharmaceutical company, from October 2004 through December 2017. He also served on the Presidential Advisory Committee for the Center for Nano and Molecular Science and Technology at the University of Texas at Austin, and was inducted into the Hall of Honor for the College of Natural Sciences at the University of Texas. Mr. Hawkins is a member of the National Ernst & Young Entrepreneur of the Year Hall of Fame. Mr. Hawkins graduated cum laude with a B.S. in Biology from Ohio University, where he later received the Ohio University Konneker Medal, the highest award given to a faculty member or former student, for entrepreneurial excellence. - Richard J. Hawkins，2007年12月以来担任公司的董事。1982年，Hawkins先生成立了Pharmaco，一个临床研究组织，后来1991年与PPD-Pharmaco的前身合并，PPD-Pharmaco如今也是最大的临床研究组织。1992年，Hawkins先生联合创立了Sensus药物研发，公司开发并且获得了SOMAVERT的监管批准，SOMAVERT是一个获得批准的生长激素拮抗剂，治疗肢端肥大症，目前由辉瑞在美国和欧洲销售，他也一直担任Sensus的董事长到2000年。1994年，Hawkins先生联合创立了Corning Biopro，一家蛋白质制造商，他一直担任董事会成员知道2000年。在2003年9月，Hawkins先生成立了LabNow，一家私营公司，研发芯片实验室传感器技术，他担任LabNow的董事长兼首席执行官一直到2009年10月。Hawkins先生2004年10月以来担任SciClone制药的董事会成员。2011年2月，Hawkins先生成为并且现在还是Lumos制药的首席执行官，这是一家刚起步的制药公司。他曾担任过奥斯汀得克萨斯大学纳米和分子科技中心的总裁顾问委员会成员，并且入选了德克萨斯大学自然科学学院荣誉大厅。Hawkins先生以优异成绩毕业于俄亥俄大学，并且拥有生物学学士学位。
- Richard J. Hawkins,founded Pharmaco, a clinical research organization, where he served as its Chairman, President and Chief Executive Officer until 1991 when it merged with the predecessor of PPD-Pharmaco. In 1992, Mr. Hawkins co-founded Sensus Drug Development Corporation, a privately-held company focused on the development of drugs to treat endocrine disorders, which developed and received regulatory approval for SOMAVERT, a growth hormone antagonist approved for the treatment of acromegaly, which is now marketed by Pfizer, Inc. (NYSE:PEE), where he served as Chairman until 2000. In 1994, Mr. Hawkins co-founded Corning Biopro, a contract protein manufacturing firm, where he served on its board until Corning BioPro's sale to Akzo-Nobel, N.V. (OTC:AKZOY), a publicly-held producer of paints, coatings and specialty chemicals, in 2000. In September 2003, Mr. Hawkins founded LabNow, Inc., a privately held company that develops lab-on-a-chip sensor technology, where he served as the Chairman and Chief Executive Officer until October 2009. In February 2011, Mr. Hawkins became Chief Executive Officer, and held the positions of Chief Executive Officer, President and Chairman of Lumos Pharma, Inc. (Nasdaq: LUMO) until the time of its sale in December 2023. Additionally, Mr. Hawkins served on the board of SciClone Pharmaceuticals, Inc. (HKD: SCLN), a publicly-held specialty pharmaceutical company, from October 2004 through December 2017. He also served on the Presidential Advisory Committee for the Center for Nano and Molecular Science and Technology at the University of Texas at Austin, and was inducted into the Hall of Honor for the College of Natural Sciences at the University of Texas. Mr. Hawkins is a member of the National Ernst & Young Entrepreneur of the Year Hall of Fame. Mr. Hawkins graduated cum laude with a B.S. in Biology from Ohio University, where he later received the Ohio University Konneker Medal, the highest award given to a faculty member or former student, for entrepreneurial excellence.
高管简历
中英对照 | 中文 | 英文- Andrew Sims
Andrew Sims于2020年2月加入Plus Therapeutics公司，担任首席财务官。在被任命为Plus Therapeutics, Inc.首席财务官之前，Sims先生曾在几家私人股本支持的公司任职。2012年至2017年，西姆斯先生担任咨询和管理咨询服务公司Amplify LLC的首席财务官。在Amplify任职后，Sims先生于2017年至2019年担任诉讼支持公司Verbatim Support Services LLC的首席财务官。他的工作重点是并购、整合、企业资本化，以及建立和管理团队以支持全球增长。此前，Sims先生是全球会计、咨询、审计、税务和咨询公司Mazars的合伙人。Sims先生在牛津、英格兰和纽约的办公室工作，审计和咨询全球公共客户，包括各种医疗保健公司，平均年收入超过10亿美元。此外，他还是50多项收购交易的主要合伙人，收购价格从500万美元到40亿美元不等。他是美国的注册会计师，英格兰和威尔士的特许会计师。西姆斯先生毕业于英国白金汉大学。
Andrew Sims,Prior to his appointment as Plus Therapeutics, Inc. Chief Financial Officer, Mr. Sims held roles at several private equity-backed companies. Between 2012 and 2017, Mr. Sims was Chief Financial Officer of Amplify LLC, an advisory and management consulting services firm. Following his time at Amplify, Mr. Sims served as Chief Financial Officer of Verbatim Support Services LLC, a litigation support company, from 2017 to 2019. His focus has been on mergers and acquisitions, integrations, corporate capitalization and building out and managing teams to support global growth. Previously, Mr. Sims was Partner at Mazars, a global accounting, advisory, audit, tax and consulting firm. Working from both the Oxford, England and New York offices, Mr. Sims audited and advised global public clients, including a variety of healthcare companies, with average annual revenues in excess of $1 billion. Further, he was the lead partner on over fifty (50) acquisitions ranging from $5 million to $4 billion in purchase price. He is a Certified Public Accountant in the U.S. and a Chartered Accountant in England and Wales. Mr. Sims is a graduate of Buckingham University in the United Kingdom.- Andrew Sims于2020年2月加入Plus Therapeutics公司，担任首席财务官。在被任命为Plus Therapeutics, Inc.首席财务官之前，Sims先生曾在几家私人股本支持的公司任职。2012年至2017年，西姆斯先生担任咨询和管理咨询服务公司Amplify LLC的首席财务官。在Amplify任职后，Sims先生于2017年至2019年担任诉讼支持公司Verbatim Support Services LLC的首席财务官。他的工作重点是并购、整合、企业资本化，以及建立和管理团队以支持全球增长。此前，Sims先生是全球会计、咨询、审计、税务和咨询公司Mazars的合伙人。Sims先生在牛津、英格兰和纽约的办公室工作，审计和咨询全球公共客户，包括各种医疗保健公司，平均年收入超过10亿美元。此外，他还是50多项收购交易的主要合伙人，收购价格从500万美元到40亿美元不等。他是美国的注册会计师，英格兰和威尔士的特许会计师。西姆斯先生毕业于英国白金汉大学。
- Andrew Sims,Prior to his appointment as Plus Therapeutics, Inc. Chief Financial Officer, Mr. Sims held roles at several private equity-backed companies. Between 2012 and 2017, Mr. Sims was Chief Financial Officer of Amplify LLC, an advisory and management consulting services firm. Following his time at Amplify, Mr. Sims served as Chief Financial Officer of Verbatim Support Services LLC, a litigation support company, from 2017 to 2019. His focus has been on mergers and acquisitions, integrations, corporate capitalization and building out and managing teams to support global growth. Previously, Mr. Sims was Partner at Mazars, a global accounting, advisory, audit, tax and consulting firm. Working from both the Oxford, England and New York offices, Mr. Sims audited and advised global public clients, including a variety of healthcare companies, with average annual revenues in excess of $1 billion. Further, he was the lead partner on over fifty (50) acquisitions ranging from $5 million to $4 billion in purchase price. He is a Certified Public Accountant in the U.S. and a Chartered Accountant in England and Wales. Mr. Sims is a graduate of Buckingham University in the United Kingdom.
- Marc H. Hedrick
Marc H. Hedrick，于2002年10月加入公司，担任首席科学官。2004年5月，他被任命为公司总裁，2014年4月被任命为首席执行官。自2002年10月加入公司以来，Hedrick博士一直担任Plus Therapeutics，Inc.董事会成员。此前，Hedrick博士曾担任多个行政领导职位，包括2001年至2003年StemSource总裁兼首席执行官，2002年至2004年Macropore生物外科首席科学官兼医疗总监。自2000年以来，Hedrick博士还担任多家公共和私人公司的董事会成员。在他的企业生涯之前，Hedrick博士是加州大学洛杉矶分校的外科和儿科副教授。在加州大学洛杉矶分校期间，Hedrick博士的学术研究获得了NIH的资助以及私人和公共资本，并通过科学出版物和媒体得到了广泛认可。Hedrick医生还拥有一手医生经验，从事普通外科、血管外科和颅面外科手术。Hedrick博士拥有德克萨斯大学西南医学院的医学学位和加州大学洛杉矶分校安德森管理学院的工商管理硕士学位，是一名训练有素的普通、血管和整形外科医生。
Marc H. Hedrick,joined the Company in October 2002 as its Chief Scientific Officer. In May 2004, he was appointed as President of the Company and in April 2014, he was appointed as its Chief Executive Officer. Dr. Hedrick has served as a member of Plus Therapeutics, Inc. board of directors (the "Board") since joining the Company in October 2002. Previously, Dr. Hedrick served in a number of executive leadership positions, including President and Chief Executive Officer of StemSource from 2001 to 2003 and Chief Scientific Officer and Medical Director of Macropore Biosurgery from 2002 to 2004. Dr. Hedrick has also served as a board member for a number of public and private companies since 2000. Prior to his corporate career, Dr. Hedrick was Associate Professor of Surgery and Pediatrics at the University of California, Los Angeles ("UCLA"). While at UCLA, Dr. Hedrick's academic research received both National Institutes of Health funding as well as private and public capitalization and was widely acknowledged through scientific publications and the media. Dr. Hedrick also has first-hand experience as a physician, practicing general, vascular and craniofacial surgery. Dr. Hedrick has a medical degree from The University of Texas Southwestern Medical School and a Master of Business Administration from the UCLA Anderson School of Management and is a trained general, vascular and plastic surgeon.- Marc H. Hedrick，于2002年10月加入公司，担任首席科学官。2004年5月，他被任命为公司总裁，2014年4月被任命为首席执行官。自2002年10月加入公司以来，Hedrick博士一直担任Plus Therapeutics，Inc.董事会成员。此前，Hedrick博士曾担任多个行政领导职位，包括2001年至2003年StemSource总裁兼首席执行官，2002年至2004年Macropore生物外科首席科学官兼医疗总监。自2000年以来，Hedrick博士还担任多家公共和私人公司的董事会成员。在他的企业生涯之前，Hedrick博士是加州大学洛杉矶分校的外科和儿科副教授。在加州大学洛杉矶分校期间，Hedrick博士的学术研究获得了NIH的资助以及私人和公共资本，并通过科学出版物和媒体得到了广泛认可。Hedrick医生还拥有一手医生经验，从事普通外科、血管外科和颅面外科手术。Hedrick博士拥有德克萨斯大学西南医学院的医学学位和加州大学洛杉矶分校安德森管理学院的工商管理硕士学位，是一名训练有素的普通、血管和整形外科医生。
- Marc H. Hedrick,joined the Company in October 2002 as its Chief Scientific Officer. In May 2004, he was appointed as President of the Company and in April 2014, he was appointed as its Chief Executive Officer. Dr. Hedrick has served as a member of Plus Therapeutics, Inc. board of directors (the "Board") since joining the Company in October 2002. Previously, Dr. Hedrick served in a number of executive leadership positions, including President and Chief Executive Officer of StemSource from 2001 to 2003 and Chief Scientific Officer and Medical Director of Macropore Biosurgery from 2002 to 2004. Dr. Hedrick has also served as a board member for a number of public and private companies since 2000. Prior to his corporate career, Dr. Hedrick was Associate Professor of Surgery and Pediatrics at the University of California, Los Angeles ("UCLA"). While at UCLA, Dr. Hedrick's academic research received both National Institutes of Health funding as well as private and public capitalization and was widely acknowledged through scientific publications and the media. Dr. Hedrick also has first-hand experience as a physician, practicing general, vascular and craniofacial surgery. Dr. Hedrick has a medical degree from The University of Texas Southwestern Medical School and a Master of Business Administration from the UCLA Anderson School of Management and is a trained general, vascular and plastic surgeon.